Table 3.
Adverse events.
| Adverse events, n (%) | Any grade | Grade 1-2 | Grade 3 | Grade 4 |
|---|---|---|---|---|
| Any | 33 (100) | 19 (58)a | ||
| Malaise | 21 (64) | 21 (64) | ||
| Anorexia | 21 (64) | 16 (49) | 5 (15) | |
| Alopecia | 19 (58) | 19 (58) | ||
| Edema limbs | 16 (48) | 14 (42) | 2 (6) | |
| Stomatitis | 13 (39) | 12 (36) | 1 (3) | |
| Constipation | 11 (33) | 11 (33) | ||
| Aspartate aminotransferase increased | 11 (33) | 11 (33) | ||
| Weight loss | 10 (30) | 10 (30) | ||
| Alanine aminotransferase increased | 8 (24) | 7 (21) | 1 (3) | |
| Peripheral sensory/motor neuropathy | 8 (24) | 8 (24) | ||
| Fever | 6 (18) | 6 (18) | ||
| Weight gain | 6 (18) | 5 (15) | 1 (3) | |
| Diarrhea | 5 (15) | 5 (15) | ||
| Vomiting | 5 (15) | 5 (15) | ||
| Creatinine increased | 5 (15) | 5 (15) | ||
| Pleural effusion | 5 (15) | 5 (15) | ||
| Hypoalbuminemia | 4 (12) | 4 (12) | ||
| Hyponatremia | 4 (12) | 1 (3) | 3 (9) | |
| Dysgeusia | 4 (12) | 4 (12) | ||
| Pneumonitis | 4 (12) | 1 (3) | 3 (9) | |
| Rash maculo-papular | 4 (12) | 4 (12) | ||
| Thrombocytopenia | 22 (67) | 21 (64) | 1 (3) | |
| Anemia | 18 (55) | 16 (48) | 2 (6) | |
| Neutropenia | 13 (39) | 5 (15) | 4 (12) | 4 (12) |
| White cell count decreased | 9 (27) | 8 (24) | 1 (3) | |
| Febrile neutropenia | 3 (9) | 3 (9) | ||
| Bleeding or hemorrhage | 11 (33) | 9 (27) | 2 (6) | |
| Oral hemorrhage | 1 (3) | 1 (3) | ||
| Epistaxis | 7 (21) | 7 (21) | ||
| Pulmonary hemorrhage events | 2 (6) | 1 (3) | 1 (3) | |
| Gastrointestinal hemorrhage | 1 (3) | 1 (3) | ||
| Proteinuria | 8 (24) | 7 (21) | 1 (3) | |
| Hypertension | 13 (39) | 11 (33) | 2 (6) | |
| Arterial/Venous thromboembolic event | 0 (0) | 0 (0) | 0 (0) |
AE; adverse event.
a
19 (58%) patients developed grade 3 or 4 AE. No grade 5 AEs was observed.